• Abivax stock is taking a hit today. Why is ABVX stock falling?The French biotech firm has been at the center of takeover rumors for months, with analysts identifying it as a potential acquisition target for large pharmaceutical companies.Eli Lilly and Co (NYSE:LLY) previously expressed interest.But management's latest comments suggest the company is not under pressure to sell and is instead focused on strengthening its financial position ahead of a potential commercialization phase.Upcoming Trial Seen As ...

Abivax is planning to raise money after releasing key trial data in June, its CEO told CNBC on Tuesday, signaling to potential buyers of the firm that it is in no rush to sell.Intense takeover rumors have surrounded the French biotech company for months, impacting the volatile stock that rose nearly 1,700% in 2025. Analysts see it as a prime takeover target, and several pharma giants have been rumored as potential buyers. A second late-stage trial assessing the long-term, maintenance effect of Abivax' lead, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report Commission file number: 001-41842 Abivax SA ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 20 ...

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind maintenance trialThe Company’s pivotal Phase 3 ABTECT maintenance trial evaluating obefazimod for moderately to severely active ulcerative colitis remains on track to report topline results in late Q2 2026Abivax appoi ...

Abivax - Abivax is developing obefazimod, a potential blockbuster therapy for chronic inflammatory diseases, currently in phase 3 trials for ulcerative colitis and phase 2b trials for Crohn's disease [2][3] - The ulcerative colitis market is projected to grow from $8.7 billion in 2026 to $14.3 billion by 2035, indicating significant market potential for obefazimod [4] - Abivax has seen a share price increase of over 1,900% in the past year, driven by positive clinical trial results and rumors of potential buyout interest from companies like Eli Lilly and AstraZeneca [6] - The company reported €589.7 million (approximately $697 million) in cash and equivalents, sufficient to fund operations into Q4 2027 [8] Nektar Therapeutics - Nektar's lead candidate, rezpegaldesleukin, has shown promising results in phase 2b trials for moderate-to-severe atopic dermatitis, with over 80% of patients achieving significant skin improvement [10] - The drug is also being tested for multiple indications, including alopecia areata, type 1 diabetes, and multiple sclerosis, enhancing its potential as a "pipeline-in-a-drug" [11] - Following a $460 million capital raise, Nektar has over $700 million in liquidity, allowing it to fund operations into 2027, with analysts projecting significant upside in stock price [12] - Nektar is considered a potential acquisition target for larger pharmaceutical companies, including Sanofi and AbbVie, which could see strategic value in its pipeline [13]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Viewpoint - Abivax, a biotechnology company, has denied takeover rumors reported by French media regarding a potential deal with AstraZeneca, stating that the claims are unfounded [1]. Company Summary - Abivax has dismissed reports from "La Lettre" that suggested it granted AstraZeneca exclusive access to confidential information until March 23 to facilitate a takeover offer [1].

Core Insights - AstraZeneca is positioned as the leading candidate to acquire Abivax following a significant increase in Abivax's valuation due to positive clinical results [1] - Abivax's stock surged approximately 1,600% in 2025, reaching a market value of about 7.7 billion euros (around $8.9 billion) [1] - AstraZeneca has exclusive access to Abivax's data room until March 23, 2025, to evaluate data and potentially formalize an acquisition offer [2] Group 1: Abivax's Drug Candidate - Abivax focuses on treatments for inflammatory diseases and has gained attention for its lead drug candidate, obefazimod (ABX464), which showed positive results in Phase 3 trials for ulcerative colitis [3][4] - The drug is expected to have a significant commercial opportunity, with nearly 70% of its potential market in the U.S., making FDA approval crucial [5] Group 2: Acquisition Dynamics - The timeline for a potential acquisition may depend on the release of additional Phase 3 trial data in late June, which could influence bidders' decisions [6] - French authorities are monitoring the acquisition closely, with any deal involving a strategic healthcare company subject to scrutiny by the Treasury Directorate General [7] Group 3: Strategic Advantages for AstraZeneca - AstraZeneca may have a political and strategic edge in the acquisition process due to its European roots, potentially facing less resistance compared to a U.S. buyer [9] - The company's CEO, Pascal Soriot, has established relationships within the French biotech sector, including with Abivax's CEO, which may facilitate the acquisition [9][10]

Group 1 - Investing in clinical-stage biotechs offers significant upside potential but comes with above-average risk, making it essential to choose wisely to avoid losses [1] - Point72 Asset Management, led by billionaire Steve Cohen, has invested in Abivax, a France-based clinical-stage biotech, which has seen its shares increase by over 1,600% in the past year [2][4] - Point72's investment strategy involves maintaining a diversified portfolio, with Abivax accounting for only 0.43% of its holdings, indicating a cautious approach to high-risk investments [3][4] Group 2 - Abivax's leading candidate, obefazimod, is being developed as a treatment for ulcerative colitis and has shown promising results in a phase 3 clinical trial, with 47% of participants having inadequate responses to prior therapies [6] - The investment model suggested includes buying a small number of shares in promising biotechs before significant clinical progress and taking profits as the stock price rises, while remaining invested for potential acquisition or approval of pipeline candidates [5]

Core Viewpoint - Shares of French biotech Abivax have increased by over 1,000% in the past year, primarily due to advancements in its leading pipeline candidate, obefazimod, which may still have significant upside potential [1]. Group 1: Potential Breakthrough - Abivax is developing obefazimod as a treatment for ulcerative colitis (UC), a market with high competition and stringent approval standards [5]. - Obefazimod has demonstrated strong efficacy in clinical trials, including a phase 3 study, and is an oral medication, unlike many existing treatments that require injections [6]. - The potential of obefazimod to disrupt the UC market is a major factor that could drive Abivax's stock price significantly higher over the next decade [6]. Group 2: Broad Potential Applicability - In addition to UC, Abivax is conducting trials to explore obefazimod's effectiveness in treating other immunological conditions, such as Crohn's disease [7]. - The company aims to expand the drug's indications, which could establish it as a leader in the immunology sector and create a multibillion-dollar franchise [8]. - With successful clinical execution across various immunology diseases, Abivax could deliver substantial returns over the next ten years [8]. Group 3: Market Valuation - Abivax is currently valued at 8.6 billion euros ($10.1 billion), a valuation that is rare for clinical-stage biotechs [9]. - The current stock price may already reflect some of obefazimod's potential success, indicating a higher bar for future stock price increases [9].